The optimism follows an announcement by Neurocrine that they have altered their partnership with Takeda on the AMPA program, ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Stifel analysts maintained a positive outlook on the company, keeping the price target steady at $166.00 following the alteration of Neurocrine's partnership with Takeda on the AMPA program.

Learn more about whether Neurocrine Biosciences, Inc. or Twist Bioscience Corporation is a better investment based on AAII's ...

Neurocrine Biosciences exceeded earnings expectations ... in its pipeline and strategic collaborations with firms like Takeda. Ingrezza's success and ongoing innovation in R&D are fundamental ...

Survey of Neurocrine Biosciences’ Crenessity suggests strong uptake across all patient segments. Sales could reach ~$1B in 2030. China’s new tariffs just reignited the same market patterns ...

Takeda Pharmaceutical Company Limited engages ... and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune ...

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily ingrezza ...

It causes your bone marrow to make too many red blood cells. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights The study met its primary endpoint and ...